TABLE 1.

Summary of Infectious Disease Pharmacy Specialty Network recommendations for appropriate use of linezolid^*

Indication	Infecting pathogen	Restrictions	Dose (IV or PO)	Duration of therapy†
Skin and soft tissue infections (complicated and uncomplicated)	Methicillin-susceptible Staphylococcus aureus	Allergy or resistance to other first-line agents for which culture and sensitivity is reported by the institution’s microbiology laboratory (beta-lactams, cephalosporins, clindamycin, cotrimoxazole, fluoroquinolones, macrolides, tetracyclines), including allergy or intolerance to vancomycin	≤30 kg adult 300 mg every 12 h, >30 kg adult 600 mg every 12 h	≤28 days
	Methicillin-resistant S aureus	Allergy or resistance to other first-line agents for which culture and sensitivity is reported by the institution’s microbiology laboratory (fusidic acid combination therapy, rifampin combination therapy [unless there is rifampin drug interaction], cotrimoxazole, clindamycin), including allergy or intolerance to vancomycin
Pneumonia	Pneumonia (PSSP, PRSP and multiresistant species)	Allergy or resistance to other first-line agents for which culture and sensitivity is reported by the institution’s microbiology laboratory (beta-lactams, cephalosporins, cotrimoxazole, fluoroquinolones, macrolides, tetracyclines), including allergy or intolerance to vancomycin	≤30 kg adult 300 mg every 12 h, >30 kg adult 600 mg every 12 h	≤28 days
	Methicillin-susceptible S aureus	Allergy or resistance to other first-line agents for which culture and sensitivity is reported by the institution’s microbiology laboratory (beta-lactams, cephalosporins, clindamycin, cotrimoxazole, fluoroquinolones, macrolides, tetracyclines), including allergy or intolerance to vancomycin
	Methicillin-resistant S aureus	Allergy or resistance to other first-line agents for which culture and sensitivity is reported by the institution’s microbiology laboratory (fusidic acid combination therapy, rifampin combination therapy [unless there is rifampin drug interaction], cotrimoxazole, clindamycin), including allergy or intolerance to vancomycin
Infection (including osteomyelitis and prosthetic joint infection)	Vancomycin-resistant enterococci	Infectious diseases specialist consultation required	≤30 kg adult 300 mg every 12 h, >30 kg adult 600 mg every 12 h	≤28 days
Osteomyelitis and prosthetic joint infection	Methicillin-resistant S aureus or coagulase-negative methicillin-resistant staphylococci	Allergy or resistance to other first-line agents for which culture and sensitivity is reported by the institution’s microbiology laboratory (fusidic acid combination therapy, rifampin combination therapy [unless rifampin drug interaction], cotrimoxazole, clindamycin), including allergy or intolerance to vancomycin	≤30 kg adult 300 mg every 12 h, >30 kg adult 600 mg every 12 h	≤28 days

^*Please see disclaimer at the end of the article;

^†Could be longer, if clinically necessary. IV Intravenous form; PO Oral form; PRSP Penicillin-resistant Streptococcus pneumoniae; PSSP Penicillin-susceptible S pneumoniae